Skip to content
HowShorted

Teladoc Health, Inc. short interest in 2024

In 2024, Teladoc Health, Inc.'s disclosed short interest ran from 13.88% of shares outstanding on 12 Jan 2024 to 13.67% on 31 Dec 2024, a change of -0.21 percentage points. The year's high was 20.57% on 15 Jul 2024 and its low 11.62% on 31 Jan 2024, averaging 15.30% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.17 days on 15 Feb 2024. Full history: Teladoc Health, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Teladoc Health, Inc. in 2024

2024 in figures

Start of year
13.88% (12 Jan 2024)
End of year
13.67% (31 Dec 2024)
Change
-0.21 pp
High
20.57% (15 Jul 2024)
Low
11.62% (31 Jan 2024)
Average
15.30%
Highest days to cover
7.17 (15 Feb 2024)
SEC filings marked
9

Every report in 2024

Teladoc Health, Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 202413.88%5.67
31 Jan 202411.62%5.24
15 Feb 202412.39%7.17
29 Feb 202413.05%2.07results (8-K), 10-K filed
15 Mar 202412.25%4.39
28 Mar 202412.61%6.66
15 Apr 202416.19%5.39results (8-K)
30 Apr 202416.46%4.95results (8-K), 10-Q filed
15 May 202415.95%4.99
31 May 202416.52%6.81
14 Jun 202415.96%6.57
28 Jun 202417.97%2.96
15 Jul 202420.57%6.96
31 Jul 202419.54%4.53results (8-K)
15 Aug 202417.06%3.6010-Q filed
30 Aug 202415.75%5.55
13 Sep 202415.77%4.83
30 Sep 202416.14%4.25
15 Oct 202414.75%6.00
31 Oct 202415.64%5.02results (8-K), 10-Q filed
15 Nov 202414.92%3.79
29 Nov 202415.24%4.16
13 Dec 202413.19%4.55
31 Dec 202413.67%5.71

See also: Teladoc Health, Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.